Nebenwirkungen · Emtriva
Emtriva 10 mg/mL oral solution · Abschnitt 4.8 · PDF-Seite 19–20
HOS-112716 · Präparat HOS-093727
19 Gastrointestinal disorders: Very common: diarrhoea, nausea Common: elevated amylase including elevated pancreatic amylase, elevated serum lipase, vomiting, abdominal pain, dyspepsia Hepatobiliary disorders: Common: elevated serum aspartate aminotransferase (AST) and/or elevated serum ALT, hyperbilirubinaemia Skin and subcutaneous tissue disorders: Common: vesiculobullous rash, pustular rash, maculopapular rash, rash, pruritus, urticaria, skin discolouration (increased pigmentation)1,2 Uncommon: angioedema3 Musculoskeletal and connective tissue disorders: Very common: elevated creatine kinase General disorders and administration site conditions: Common: pain, asthenia 1 See section 4.8, Description of selected adverse reactions for more details. 2 Anaemia was common and skin discolouration (increased pigmentation) was very common when emtricitabine was
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-04-18T12:34:00Z · SHA-256 4ee4f99346bca4db5449cf522784d6dbc4cba891b89d833a052a1c777428bfcb · Passage 95283df43eb0825f62d06d25ffa73262d2f40f4bf3ca2833cbe8406013166a92 · Zeichen 2099–3138 im Abschnitt